Last reviewed · How we verify
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
The overall objective of the proposed study is to determine if lofexidine (LFX) as an adjunct to buprenorphine (BUP) treatment improves symptoms of both opioid use disorder (OUD) and Post-Traumatic Stress Disorder (PTSD). Other study objectives are to compare the safety, tolerability, and efficacy of BUP treatment alone, to BUP treatment with adjunct LFX, on measures of OUD and PTSD symptoms in Veterans with both prognosis .
Details
| Lead sponsor | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 120 |
| Start date | Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Post Traumatic Stress Disorder
- Opioid-use Disorder
Interventions
- Lofexidine
- Placebo oral tablet
Countries
United States